AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 1st, 2022 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 to the Collaboration Agreement (this “Amendment”) is effective as of the 27th day of October, 2021 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”) and CytomX Therapeutics, Inc., a Delaware corporation having an address at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (“CytomX”). Amgen and CytomX are each hereafter referred to individually as a “Party” and together as the “Parties”.
